Table of Contents Author Guidelines Submit a Manuscript
International Journal of Analytical Chemistry
Volume 2015, Article ID 210503, 9 pages
http://dx.doi.org/10.1155/2015/210503
Research Article

Micellar Enhanced Spectrofluorimetric Method for the Determination of Ponatinib in Human Plasma and Urine via Cremophor RH 40 as Sensing Agent

1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
2Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt
3Quality Management Department, National Guard Health Affairs, King Abdulaziz Medical City, P.O. Box 22490, Riyadh 11426, Saudi Arabia

Received 22 October 2015; Revised 7 December 2015; Accepted 14 December 2015

Academic Editor: Josep Esteve-Romero

Copyright © 2015 Hany W. Darwish et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W.-S. Huang, C. A. Metcalf, R. Sundaramoorthi et al., “Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant,” Journal of Medicinal Chemistry, vol. 53, no. 12, pp. 4701–4719, 2010. View at Publisher · View at Google Scholar
  2. E. Weisberg, P. W. Manley, S. W. Cowan-Jacob, A. Hochhaus, and J. D. Griffin, “Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia,” Nature Reviews Cancer, vol. 7, no. 5, pp. 345–356, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. T. O'Hare, W. C. Shakespeare, X. Zhu et al., “AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance,” Cancer Cell, vol. 16, no. 5, pp. 401–412, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. U.S. Food and Drug Administration (FDA), Ponatinib, Center for Drug Evaluation and Research, Silver Spring, Md, USA, 2012.
  5. V. Prasad and S. Mailankody, “The accelerated approval of oncologic drugs lessons from ponatinib,” The Journal of the American Medical Association, vol. 311, no. 4, pp. 353–354, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. U.S. Food and Drug Administration (FDA), Ponatinib, Center for Drug Evaluation and Research, Silver Spring, Md, USA, 2013.
  7. M. Senior, “FDA halts then allows sales of Ariad's leukemia medication,” Nature Bbiotechnology, vol. 32, no. 1, pp. 9–11, 2014. View at Google Scholar
  8. Z. Aydoǧmuş, F. Sari, and S. T. Ulu, “Spectrofluorimetric determination of aliskiren in tablets and spiked human plasma through derivatization with dansyl chloride,” Journal of Fluorescence, vol. 22, no. 2, pp. 549–556, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Balwani, E. Joseph, S. Reddi, V. Nagpal, and R. N. Saha, “Rapid, simple, and sensitive spectrofluorimetric method for the estimation of ganciclovir in bulk and pharmaceutical formulations,” Journal of Spectroscopy, vol. 2013, Article ID 972806, 5 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Kaur, S. S. Saini, A. K. Malik, and B. Singh, “Micelle enhanced and terbium sensitized spectrofluorimetric determination of danofloxacin in milk using molecularly imprinted solid phase extraction,” Spectrochimica Acta—Part A: Molecular and Biomolecular Spectroscopy, vol. 96, pp. 790–795, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Tang, X. Wang, B. Jia et al., “Simple, rapid, and sensitive spectrofluorimetric determination of Zaleplon in micellar medium,” Analytical Letters, vol. 36, no. 14, pp. 2985–2997, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. C. C. Wang, A. N. Masi, and L. Fernández, “On-line micellar-enhanced spectrofluorimetric determination of rhodamine dye in cosmetics,” Talanta, vol. 75, no. 1, pp. 135–140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. B. Ghasemi and E. Zolfonoun, “Application of principal component analysis-multivariate adaptive regression splines for the simultaneous spectrofluorimetric determination of dialkyltins in micellar media,” Spectrochimica Acta—Part A: Molecular and Biomolecular Spectroscopy, vol. 115, pp. 357–363, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Hanguo, G. Xiaoxia, L. Yan, and L. Sengtie, “Fluorometric determination of trace amounts of samarium end europium in geological samples with thenoyltrifluoroacetone-ophenanthroline tween 20 micellar system,” Analytical Laboratory, vol. 9, p. 6, 1987. View at Google Scholar
  15. M. I. Walash, F. Belal, M. M. Tolba, and M. I. Halawa, “Micelle-enhanced spectrofluorimetric determination of amlexanox in bioadhesive buccal tablets: application to content uniformity testing,” Luminescence, vol. 30, no. 6, pp. 823–829, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. N. A. Alarfaj and M. F. El-Tohamy, “Determination of the anti-viral drug Ribavirin in dosage forms via micelle-enhanced spectrofluorimetric method,” Luminescence, vol. 28, no. 2, pp. 190–194, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. R. M. Maggio, G. N. Piccirilli, and G. M. Escandar, “Fluorescence enhancement of carbendazim in the presence of cyclodextrins and micellar media: a reappraisal,” Applied Spectroscopy, vol. 59, no. 7, pp. 873–880, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. J. J. B. Nevado, J. A. M. Pulgarín, and M. A. G. Laguna, “Spectrofluorimetric study of the β-cyclodextrin: vitamin K3 complex and determination of vitamin K3,” Talanta, vol. 53, no. 5, pp. 951–959, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. H. W. Darwish, A. S. Abdelhameed, A. H. Bakheit, and A. M. Alanazi, “A new method to determine the new C-Met inhibitor ‘Cabozantinib’ in dosage form and human plasma via micelle-enhanced spectrofluorimetry,” RSC Advances, vol. 5, no. 51, pp. 40484–40490, 2015. View at Publisher · View at Google Scholar
  20. H. W. Darwish and A. H. Bakheit, “Micellar enhanced synchronous spectrofluorimetric method for determination of dasatinib in tablets, human plasma and urine: application to in vitro drug release and content uniformity test,” RSC Advances, vol. 5, no. 67, pp. 54471–54480, 2015. View at Publisher · View at Google Scholar
  21. A. Christiansen, T. Backensfeld, and W. Weitschies, “Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes,” European Journal of Pharmaceutical Sciences, vol. 41, no. 2, pp. 376–382, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. C. D. O. Rangel-Yagui, A. Pessoa Jr., and L. C. Tavares, “Micellar solubilization of drugs,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 8, no. 2, pp. 147–163, 2005. View at Google Scholar · View at Scopus
  23. R. Leung and D. O. Shah, “Dynamic properties of micellar solutions. I. Effects of short-chain alcohols and polymers on micellar stability,” Journal of Colloid And Interface Science, vol. 113, no. 2, pp. 484–499, 1986. View at Publisher · View at Google Scholar · View at Scopus
  24. Committee for Medicinal Products for Human Use (CHMP), Guideline on Bioanalytical Method Validation, European Medicines Agency, 2011.
  25. J. N. Millerand and J. C. Miller, Statistics and Chemometrics for Analytical Chemistry, Pearson Education, 2005.
  26. N. I. Narasimhan, D. J. Dorer, K. Niland, F. Haluska, and D. Sonnichsen, “Effects of food on the pharmacokinetics of ponatinib in healthy subjects,” Journal of Clinical Pharmacy and Therapeutics, vol. 38, no. 6, pp. 440–444, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. N. I. Narasimhan, D. J. Dorer, J. Davis, C. D. Turner, T. C. Marbury, and D. Sonnichsen, “Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects,” Cancer Chemotherapy and Pharmacology, vol. 74, no. 2, pp. 341–348, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. S. M. Hoy, “Ponatinib: a review of its use in adults with chronic myeloid leukaemia or philadelphia chromosome-positive acute lymphoblastic leukaemia,” Drugs, vol. 74, no. 7, pp. 793–806, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. J. R. Lakowicz, Principles of Fluorescence Spectroscopy, Springer, 2007.